GlassScriptPhysician profile
Brady Cade Blackham
NPI 1679701197
$2,120.65
in general payments reported to CMS, 2019-2025
26 companies · $236 in 2025
The $236 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $76.13 · 2020: $235 · 2021: $295 · 2022: $308 · 2023: $567 · 2024: $402 · 2025: $236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,106 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,105.96 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $529.75 | 2021-2025 | Vraylar, Ubrelvy |
| Xeris Pharmaceuticals, INC. | $191.80 | 2022-2024 | Gvoke Hypopen |
| Lilly USA, LLC | $164.43 | 2020-2025 | Mounjaro |
| Merck Sharp & Dohme LLC | $136.14 | 2019-2025 | Gardasil 9, Capvaxive, Vaxelis |
| Pfizer INC. | $128.18 | 2020-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.35 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Supernus Pharmaceuticals, INC. | $119.32 | 2020-2025 | Qelbree |
| Sanofi Pasteur INC. | $101.05 | 2019-2023 | |
| Astellas Pharma US INC | $99.99 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $60.20 | 2021-2023 | Breztri, Farxiga |
| Allergan, INC. | $47.66 | 2020 | |
| Organon LLC | $46.08 | 2021-2023 | Nexplanon |
| Boston Scientific Corporation | $44.76 | 2023 | |
| Glaxosmithkline, LLC. | $38.97 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $38.85 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $38.63 | 2020 | |
| Novo Nordisk INC | $35.50 | 2020-2021 | |
| Harmony Biosciences LLC | $35.24 | 2024 | |
| Horizon Therapeutics Plc | $30.85 | 2022 | |
| Edwards Lifesciences Corporation | $18.96 | 2022 | |
| Ibsa Pharma INC. | $17.88 | 2023 | Tirosint, Licart |
| Mylan Specialty L.P. | $17.67 | 2023 | Yupelri |
| Amgen INC. | $16.58 | 2023 | Prolia, Evenity |
| Agile Therapeutics, INC. | $15.05 | 2024 | Twirla |
| Indivior INC. | $13.39 | 2023 | Sublocade |
| Idorsia Pharmaceuticals US INC | $13.37 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brady Blackham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.